Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is well-positioned for growth with a strong focus on expanding their brand and investing in technology and efficiency, while also prioritizing risk management. The company's revenue growth and resilience during challenging times show their potential for long-term success. However, there are risks in the industry that could impact their growth, such as high capital investment and changes in reimbursement policies. Overall, Medline has a positive outlook with strong fundamentals and potential for continued growth in the future.

Bears say

Medline is a dominant player in the US medical-surgical products and supply chain market, with significant scale, a wide range of products, and a comprehensive distribution strategy. However, the company's high reliance on domestic revenue and single-vendor relationships may make it vulnerable to changes in the healthcare industry and potential disruptions. Additionally, the recent acquisition and going public may bring increased pressure for performance and possible changes in management and operations.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Sep 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $47.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $47.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.